Platinum-resistant Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Platinum-resistant Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-24Clinical Trial Results: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial results for elenagen plasmid in combination with gemcitabine show efficacy in platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S vs investigator's choice in platinum-resistant ovarian cancer; study status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; status active_not_recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
Phase 3 trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer [Phase 1]
Phase 1 trial evaluating adding abemaciclib to olaparib in women with recurrent ovarian cancer, including high-grade serous and platinum-res…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors [Phase 1]
NiKang Therapeutics is conducting a Phase 1 study of NKT3964 in adults with advanced or metastatic solid tumors, and the trial is currently …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors [Phase 1]
Context Therapeutics reports an ongoing Phase 1 study of CTIM-76 in platinum-resistant ovarian cancer and other advanced solid tumors, with …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]
Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 trial evaluating HWK-007, a PTK7-directed antibody-drug conjugate, for advanced solid tumors; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]
This clinical trial update reports the completion of a Phase 1/2 study evaluating the combination of Azenosertib (ZN-c3) and Niraparib in pl…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) [Phase 3]
Phase 3 clinical trial evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and Bevacizumab versus physician's choice of ch…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. [Phase 1]
This clinical trial update outlines a Phase 1 study of HWK-016, a MUC16-directed antibody-drug conjugate, in participants with advanced soli…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. [Phase 1]
This Phase 1 study is evaluating the safety and potential efficacy of WSK-IM02 in patients with platinum-resistant ovarian cancer, with the …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer [Phase 3]
A Phase 3 clinical trial evaluating Rina-S versus investigator's choice in platinum-resistant ovarian cancer; the study is currently active …
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers [Phase 1]
Phase 1b study evaluating SL-172154 in combination with other agents in platinum-resistant ovarian, fallopian tube, and primary peritoneal c…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer [Phase 1]
A Phase 1 clinical trial to evaluate the safety and efficacy of OPB-101 in platinum-resistant ovarian cancer is ongoing. The study is curren…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian [Phase 2]
A phase 2 trial evaluating afuresertib in combination with paclitaxel for platinum-resistant ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) [Phase 3]
A Phase 3 study assessing nemvaleukin alfa in combination with pembrolizumab for platinum-resistant ovarian cancer has been terminated. Resu…
-
CLINICAL_TRIALS research · 2025-08-28Clinical Trial Update: Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer [Phase 2]
Phase 2 clinical trial update examining etoposide capsules plus bevacizumab, iparomlimab, and tuvonralimab for platinum-resistant or platinu…
-
CLINICAL_TRIALS research · 2025-07-20Clinical Trial Update: Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study [Phase 4]
A prospective multicenter Phase 4 trial is assessing the safety and efficacy of combining RIF with Anlotinib in patients with advanced recur…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating IN10018 in combination with pegylated liposomal doxorubicin versus PLD with placebo in platinum-resistant recurre…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 trial (IN10018) evaluating IN10018 in combination with standard chemotherapy for high-grade serous epithelial ovarian cancer is …
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer [Phase 2, Phase 3]
A Phase 2/3 trial evaluating PCC + Bevacizumab + CA4P vs PCC + Bevacizumab + Placebo for platinum-resistant ovarian cancer was terminated, w…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1]
A Phase 1 trial evaluates the combination of mirvetuximab soravtansine and rucaparib camsylate in patients with recurrent gynecologic cancer…
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) [Phase 1, Phase 2]
GI Innovation's GI-102 is being studied in a phase 1/2 trial as a single agent and in combination with pembrolizumab or trastuzumab deruxtec…